Skip to main content
. 2020 May;9(5):3222–3230. doi: 10.21037/tcr.2020.04.07

Figure 1.

Figure 1

Kaplan-Meier curves. PFS for eligible patients with solid tumors harboring a PIK3CA mutation or amplification treated with sirolimus. PFS, progression-free survival; CI, confidence interval.